Initiating antiretroviral therapy during HIV infection: Confusion and clarity

JAMA

Volumn 286, Issue 20, 2001, Pages 2597-2599

  Pomerantz, R J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ANTIVIRAL ACTIVITY; CELL COUNT; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG INDUCED DISEASE; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT PLANNING; VIRUS LOAD;

EID: 0035965636     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.20.2597     Document Type: Editorial

References (27)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Prolongation of life prevention of AIDS complications in a randomized controlled clinical trial of ritonavir in patients with advanced HIV disease
3. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial: Italy the Netherlands, Canada and Australia Study
4. Residual HIV-1 infection during antiretroviral therapy: The challenge of viral persistence
5. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
6. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy
7. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count viral load
8. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy
9. When to start highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the ICONA study
10. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy
11. Predictors of a viral response subsequent virological treatment failure in patients with HIV starting a protease inhibitor
12. Predictors of optimal virological response to potent antiretroviral therapy
13. Sex differences in HIV-1 viral load progression to AIDS
14. + lymphocyte counts and the risk of progression to AIDS
15. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: A predictor of long-term mortality in HIV infection
16. + lymphocytes as prognostic markers of HIV-1 infection
17. + cell count rate of progression to AIDS following acute HIV-1 infection
18. Shorter survival in advanced human immunodeficiency virus type I infection is more closely associated with T-lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage
19. Human immunodeficiency virus type I subtypes differ in disease progression
20. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
21. The impact of protease inhibitor containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 viral load
22. Long-term survival after initiation of antiretroviral therapy
23. + lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART
24. + lymphocytes < 200 cells/mL) is associated with increased risk of death
25. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA Study
26. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome